SoftScan, a product of Canadian firm Advanced Research Technologies Inc., has been approved for sale in O’Canada for the diagnosis of breast cancer. As we reported earlier, the device’s innovative optical imaging diagnostic technology is based on the fact that malignancies have increased tissue perfusion and metabolism.
The company explains its device:
SoftScan is an optical imaging device for the detection, diagnosis and characterization of breast cancer. The information obtained from SoftScan addresses a critical and unmet need in breast tissue analysis. This need is for a device that provides functional or physiological information about a lesion, such as tissue perfusion and blood oxygen content, and that allows characterization of a lesion as benign or malignant.
The SoftScan system is comprised of a patient table, scanning accessories, an optical acquisition unit, and a processing and display workstation installed on a separate mobile unit. In a clinical setting, the SoftScan system can be installed in any type of space similar in size to a stereotactic biopsy suite.